In 2023, the plasma fractionation market was valued at approximately $32.75 billion. By 2034, this market is expected to surge to $72.86 billion, reflecting an impressive compound annual growth rate (CAGR) of 7.54% from 2024 to 2034. This rapid growth is fueled by the increasing demand for plasma-based therapies, which continue to drive advancements and opportunities within the industry.
Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5320
North America held the largest share of the global plasma fractionation market in 2023, with the United States as the world’s top plasma supplier. The U.S. operates a paid donor system, unlike many other countries that rely on unpaid, volunteer donors, leading to significantly higher plasma collection rates. Canadian Blood Services leverages raw plasma for producing drugs like plasma proteins and related products. In the U.S., three major plasma product companies—CSL Plasma, Grifols, and BioLife—collect over 75% of the total plasma used for fractionation. Notably, the number of plasma donation centers in the U.S. has increased by 54% over the past four years. With the growing demand for plasma, estimated at 6,500 units daily, maintaining a consistent donation rate remains crucial for meeting global needs.
Europe is projected to experience the fastest growth in the plasma fractionation market between 2024 and 2034. This growth is driven by the European Union’s focus on achieving open strategic autonomy and enhancing competitiveness in the plasma sector. Collaborative efforts by EU institutions, governments, and businesses aim to address vulnerabilities and implement policies that ensure a resilient supply of plasma and plasma-derived medicinal products. These measures are expected to strengthen both regional and national strategies, fostering recognition and sustainability in Europe’s plasma fractionation industry.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/plasma-fractionation-market-sizing
Access exclusive insight now @ https://www.towardshealthcare.com/price/5320
We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com
Web: https://www.towardshealthcare.com
Visit Dental Specifics: https://www.towardsdental.com
Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
Kedrion Biopharma has announced that its human coagulation factor X concentrate, COAGADEX®, has been granted orphan drug designation by the… Read More
enecard PBF, a pioneer in pharmacy benefit facilitation, has announced a strategic partnership with DecisionRX, Inc., a leader in medication… Read More
In a high-stakes biotech industry where drug development can span over a decade, four small but determined biotech companies are… Read More
cell-free DNA and precision medicine, has officially announced the launch of the TEODOR trial (ABCSG 61), a groundbreaking phase 2,… Read More
The global interventional radiology market is witnessing rapid expansion, driven by advancements in minimally invasive procedures, rising demand for diagnostic… Read More
The global physical therapy market is valued at USD 28.06 billion in 2024, growing to USD 29.18 billion in 2025… Read More